COMMUNIQUÉS West-GlobeNewswire

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2025
09/06/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - May 2025
09/06/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
09/06/2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging [...]
Circuit Clinical Solutions Inc. [“Circuit Clinical”] and Lightship Inc. [“Lightship”] Announce Strategic Merger to Accelerate Scale and Expanded Access in Clinical Research
09/06/2025
BUFFALO, N.Y. and MORRISVILLE, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Today, Lightship and Circuit Clinical proudly announce their strategic merger, forming a leading, unified force in clinical trial delivery. This [...]
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
09/06/2025
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
Micron Biomedical Names Health Education and Empowerment Advocate, Dr. Jayne Morgan, to Board of Advisors
09/06/2025
Role will focus on helping to inform and build public trust in vaccine and therapy options that are delivered without injections, through dissolvable technology ATLANTA, June 09, 2025 (GLOBE NEWSWIRE) -- Micron [...]
Medicovestor, Inc. and Sanyou Biopharmaceuticals Forge Strategic Partnership to Develop First-in-Class Chemoimmunotherapy Antibody-Drug Conjugates
09/06/2025
NEW YORK and SHANGHAI, June 09, 2025 (GLOBE NEWSWIRE) -- Medicovestor, Inc., a New York-based biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs) today announced a [...]
New medial stabilized insert for Smith+Nephew’s LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility
09/06/2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a [...]
BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors
09/06/2025
Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig”), which acquired Streamex Exchange Corporation as its wholly owned subsidiary (“Streamex”) in May [...]
Keros Announces Return of $375 Million in Excess Capital to Stockholders
09/06/2025
Concludes Strategic Alternatives Review and Provides Update on Development of KER-065 LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical- [...]
George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment
09/06/2025
Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy , with an established safety profile and good tolerability First and only [...]
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
09/06/2025
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ [...]
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
09/06/2025
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of [...]
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
09/06/2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has [...]
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
09/06/2025
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the [...]
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
09/06/2025
Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a [...]
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
09/06/2025
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no [...]
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
09/06/2025
KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative molecular glues and [...]
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
09/06/2025
Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09 [...]

Pages